
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p

– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p
NewAmsterdam Pharma Company N.V. on 6ix
Follow NewAmsterdam Pharma into a list and get an email when it puts out news.
Follow NewAmsterdam Pharma